血小板减少在早产儿中很常见,并可能与出血有关。大多数血小板输注是预防性的。以前,建议新生儿使用较高的血小板计数阈值,但这一建议在最近的研究中受到质疑。在PlaNeT2试验中,血小板计数阈值最高的新生儿的死亡率和严重出血发生率高于其他新生儿.在这次审判之后,我们通过将预防性输血的血小板计数阈值从50,000降至25,000/mm3,改变了我们的血小板输注实践.我们进行了一项前后回顾性队列研究,以量化血小板输注频率,并通过分析死亡和严重出血事件来评估新方案。这项回顾性单中心研究包括妊娠37周前出生的新生儿,在新的血小板输注方案之前的2年内,其血小板计数<150,000/mm3(高预防性输血阈值,50,000/mm3)和新的血小板输注方案后的2年内(低预防性输血阈值,25,000/mm3)。主要结局是两组中接受至少一次血小板输注的新生儿比例。我们还比较了死亡和严重出血事件的比例。共发现707例血小板减少新生儿。在高门槛组中,99/360(27.5%)接受了至少一次血小板输注,而低阈值组则为56/347(16.1%)(p<0.001)。两组在死亡或严重出血事件的比例上没有差异。
结论:血小板计数阈值降低可显著减少血小板输注次数,而不增加严重出血事件。
背景:•最近的一项随机试验表明,血小板输注的限制性血小板计数阈值可能对早产新生儿有益。
背景:•将输血的血小板计数阈值从50,000降低至25,000/mm3时,新生儿重症监护病房的输血次数显著减少,但不增加严重出血事件。
Thrombocytopenia is common in preterm neonates and can be associated with hemorrhage. Most platelet transfusions are prophylactic. Previously, higher platelet-count thresholds were recommended for neonates, but this recommendation has been questioned in recent studies. In the PlaNeT2 trial, mortality and serious bleeding were more frequent in neonates with the highest platelet-count
threshold than in others. Following this trial, we changed our platelet transfusion practice by lowering the platelet-count
threshold for prophylactic transfusion from 50,000 to 25,000/mm3. We conducted a before-after retrospective cohort study to quantify the frequency of platelet transfusions and assess the new protocol by analyzing death and serious hemorrhage events. This retrospective monocentric study included neonates born before 37 weeks of gestation with platelet count < 150,000/mm3 during the 2 years preceding the new platelet transfusion protocol (high prophylactic transfusion threshold, 50,000/mm3) and during the 2 years after the new platelet transfusion protocol (low prophylactic transfusion threshold, 25,000/mm3). The primary outcome was the proportion of neonates receiving at least one platelet transfusion in both groups. We also compared the proportion of deaths and severe hemorrhage events. A total of 707 neonates with thrombocytopenia were identified. In the high-
threshold group, 99/360 (27.5%) received at least one platelet transfusion as compared with 56/347 (16.1%) in the low-
threshold group (p < 0.001). The groups did not differ in proportion of deaths or severe hemorrhage events.
CONCLUSIONS: A reduced platelet-count
threshold for transfusion allowed for a significant reduction in the number of platelet transfusions without increasing severe hemorrhage events.
BACKGROUND: • A recent randomized trial suggested that restrictive platelet-count thresholds for platelet transfusion could be beneficial for preterm neonates.
BACKGROUND: • On lowering the platelet-count threshold for transfusion from 50,000 to 25,000/mm3, the number of transfusions significantly decreased without increasing severe hemorrhage events in a neonatal intensive care unit.